Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.

[1]  I. Thompson,et al.  Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[2]  Thierry Gil,et al.  Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. , 2013, The Lancet. Oncology.

[3]  Steve Y. Cho,et al.  A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer , 2013, Cancer Chemotherapy and Pharmacology.

[4]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[5]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[6]  I. Tannock,et al.  Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. , 2012, Urologic oncology.

[7]  P. Kantoff,et al.  Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Staffurth,et al.  A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. , 2012, European journal of cancer.

[9]  D. Tsavachidou,et al.  Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Armstrong,et al.  Dasatinib combined with docetaxel for castration‐resistant prostate cancer , 2012, Cancer.

[11]  C. Logothetis,et al.  Novel therapies for metastatic castrate-resistant prostate cancer. , 2011, Journal of the National Cancer Institute.

[12]  J. Waxman,et al.  Bone metastasis in prostate cancer: emerging therapeutic strategies , 2011, Nature Reviews Clinical Oncology.

[13]  J. Waxman,et al.  Bone metastasis in prostate cancer: emerging therapeutic strategies , 2011, Nature Reviews Clinical Oncology.

[14]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[15]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[16]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[17]  Manuel Ayala,et al.  Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. , 2010, The New England journal of medicine.

[18]  M. Gordon.  Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .

[19]  Christophe Massard,et al.  Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer , 2009, Clinical Cancer Research.

[20]  C. Logothetis,et al.  Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation , 2009, Cancer biology & therapy.

[21]  R. Vessella,et al.  Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis , 2009, British Journal of Cancer.

[22]  Thomas J Mitchell,et al.  Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer , 2009, Clinical Cancer Research.

[23]  P. Febbo,et al.  Genomic strategy for targeting therapy in castration-resistant prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Gurkamal Chatta,et al.  A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study , 2009, Anti-cancer drugs.

[25]  Zhengxin Wang,et al.  Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. , 2008, Cancer research.

[26]  P. Nelson,et al.  Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[27]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  F. Lee,et al.  Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor , 2008, Cancer Chemotherapy and Pharmacology.

[29]  K. Fizazi,et al.  The role of Src in prostate cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  C. Cleeland.  The Measurement of Pain from Metastatic Bone Disease: Capturing the Patient's Experience , 2006, Clinical Cancer Research.

[31]  P. Ji,et al.  Dasatinib (BMS-354825) pharmacokinetics correlate with pSRC pharmacodynamics in phase I studies of patients with cancer (CA180002, CA180003). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[33]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[34]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[35]  Archana Sanjay,et al.  Src Kinase Activity Is Essential for Osteoclast Function* , 2004, Journal of Biological Chemistry.

[36]  C. Cleeland,et al.  Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases , 1983, Pain.

[37]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.